rq-00000010
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2016 (NCT02838797)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Serotonin 4 (5-HT4) receptorPARTIAL AGONIST
HTR4 partial agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- rq-00000010
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02838797 | Phase 1 | Jun 1, 2016 | Michael J. Fox Foundation for Parkinson's Research, RaQualia Pharma Inc., Virginia Commonwealth University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Michael J. Fox Foundation for Parkinson's Research | Academic/Hospital | 1 | 0 | 1 | 2016 |
| RaQualia Pharma Inc. | For profit | 1 | 0 | 1 | 2016 |
| Virginia Commonwealth University | Academic/Hospital | 1 | 1 | 1 | 2016 |
3 organizations
Page 1 / 1